Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Abbott To Buy AP214 From Action Pharma - Quick Facts

Abbott (ABT: Quote) and Action Pharma A/S, a privately owned company, have reached an agreement in which Abbott would acquire AP214 from Action Pharma. The company said this acquisition would enhance Abbott's pipeline in renal care. Abbott has two investigational treatments in development for chronic kidney disease.

Pursuant to the deal, Abbott would buy all global rights to develop and commercialize AP214 for the prevention of AKI and other relevant indications. Abbott would provide a cash payment of $110 million to Action Pharma and woul be responsible for funding all future development and commercialization activities regarding AP214. No later milestone payments or royalties would be paid to Action Pharma.

Abbott expects to incur a one-time specified item in the second quarter of 2012, related to this payment.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%. Here is a quick summary of the earnings reported after the bell on Nov. 24. 1. Amira Nature Foods Ltd (ANFI) reported net income for the second quarter of $8.3 million or $0.29 per share, compared to $5.0 million or $0.18 per share for the year-ago quarter. Excluding items, adjusted earnings...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.